IMMI24 is a medical organization in the Netherlands with the purpose of helping and informing patients and developing and producing therapies, in particular immunotherapies such as GcMAF. We work with other clinics and doctors both Worldwide, as well as with various institutions conducting clinical trials and doing research & development.

GcMAF (Gc Protein derived Macrophage Activating Factor) occurs naturally in our bodies and instructs macrophages to destroy cancerous cells and foreign invaders by activating them.

Macrophages (Greek: big eaters) are cells originating from monocytes, a type of white blood cell found in the body. Macrophages function in both non-specific defense (innate immunity) as well as help initiate specific defense mechanisms (adaptive immunity) of vertebrate animals.

Their role is to phagocytize (engulf and then digest) cellular debris and pathogens, either as stationary or as mobile cells. They also stimulate lymphocytes and other immune cells to respond to pathogens. They are specialized phagocytic cells that attack foreign substances, infectious microbes and cancer cells through destruction and ingestion.

A macrophage of a mouse stretching its “arms” (pseudopodia) to engulf two particles, possibly pathogens.

Skin *macrophages, resident Langerhans cells, dendritic cells, mast cells
Gut and intestinal Peyer’s patches *macrophages
Lungs *macrophages, monocytes, mast cells, dendritic cells
Bloodneutrophils, monocytes
Bone marrowmacrophages, monocytes, sinusoidal cells, lining cells
Connective tissuemacrophages, monocytes, dendritic cells, histiocytes
Lymphoid tissuemacrophages, monocytes, dendritic cells
Spleenmacrophages, monocytes, sinusoidal cells
Thymusmacrophages, monocytes

* These locations offer the best sites for GcMAF-Forte administration. The skin by subcutaneous (SC) or intramuscular (IM) injection, the gut by oral administration and the lungs by inhalation using a nebulizer.

GcMAF-Forte is a glycoprotein that activates macrophages which in turn increases macrophage activity and transforms them into Natural Killer (NK) cells.

  • Best in Class
  • Slow Release over 7 days
  • Activation of Endogenous GcMAF
  • No Side effects
  • Contains No Human Materials


GcMAF-Forte is produced using our new Patent Pending process which was developed here in Singapore or Switzerland for IMMI24 in collaboration with Dr. M.C.

GcMAF-Forte is made using a new and improved method of Gc-MAF production which much more concentrated and is more active and stable than other GcMAF that is currently available. Importantly, this much higher concentration GcMAF-Forte has been clinically demonstrated to be largely free of any side effects in the great majority of patients and is much more stable because it is resistant to oxidation and has no Human substances.

GcMAF-Forte is stable for a minimum of 2 years at room temperature. We completed a longer stability experiment which found that GcMAF-Forte is stable for 2 years at room temperature without loss in macrophage activation activity so the GcMAF-Forte remains highly potent.

In addition to GcMAF-Forte we produce different peptides, mito-organella and Nano detoxification. We are continuously researching and developing new immunotherapies for patients in collaboration with various institutions in the hole world.



Gc-MAF macrophage activation therapy is indicated in the treatment of any diseases where there is immune disfunction or where the immune system is compromised, such as:


CancerAutoimmune diseasesEpstein-Barr Virus (EBV)
Hepatitis B virus (HBV)Herpes Simplex virus (HSV)Cystitis
Hepatitis C virus (HCV)Multiple sclerosis (MS)Urinary tract infection (UTI)
Autism Spectrum Disorders (ASD)Rheumatoid arthritis (RA)Endometriosis
Chronic Fatigue Syndrome (CFS)Lyme disease (Lyme borreliosis)IgA deficiency disorder
Myalgic Encephalomyelitis (ME)Mycobacteria infectionsParkinson’s disease
TuberculosisFibromyalgiaHuman papillomavirus (HPV)
Lupus (Systemic lupus erythematosus, SLE)HIV AIDSDengue fever
Pneumonia infectionWarts caused by viral infectionNorovirus
MalariaInfluenza virus (flu)Herpes simplex virus (HSV)
Q fever (Coxiella burnetii)Polycystic ovary syndrome (PCOS)Chicken pox (varicella zoster virus)
PsoriasisRespiratory tract infectionsUlcerative colitis, Crohn’s disease
Type 1 diabetes (T1DM), insulin-dependent diabetes (IDDM)Type 1.5 diabetes, Latent autoimmune diabetes of adults (LADA).

Cancer: GcMAF-Forte therapy we recommend 2 ml High Dose GcMAF (1 vial) for 10-20 weeks in an integrative approach to treating cancer.

Other diseases (such as Autism, CFS, ME, Lyme disease): We recommend 2 ml High Dose GcMAF (1 vial) once a week. Period of time may be required depending on the initial response.

We also create your own treatment plan, ask us for more information.

GcMAF-Forte is administered by subcutaneous (SC) or intravenous (IV) injection, 1 time per week (or as prescribed by the treating medical doctor) using a Size 26G x 1/2″ (0.45 x 13 mm) or Size 27G needle with a 2.5 ml or 2 ml syringe (single use, sterile disposable). The larger 2.5 ml syringe is easier to use due to the shorter plunger stroke distance necessary during injection. Diabetes needles may also be sufficient for administration of GcMAF-Forte, although these are a finer needle.

Treatment in our clinics has also been by subcutaneous (SC) and intravenous (IV) injection, although IM and SC injection is by far the most common means of administration for most patients.

Various other methods of administration are possible:

Intravenous (IV) injection
GcMAF-Forte may be administered by intravenous (IV) infusion (drip) or by push IV. The usual dose is 2 ml once a week in 20 ml or more saline. When given by push IV, 20 ml saline and GcMAF-Forte solution is administered in a 20 or 30 ml syringe for 3 minutes or longer.

Inhalation of GcMAF-Forte using a Nebulizer
Another option of administration is using a Nebulizer to activate macrophages in the bronchus-associated lymphoid tissue (BALT) of the lungs, for example, using a device such as the Omron NE-U22 Portable Nebuliser. This method of administration is particularly well suited to diseases of the lungs where local administration can have greater effect.

Omron NE-U22 Portable Nebuliser

Omron NE-U22 Portable Nebuliser for administration in the lungs to activate macrophages in the Bronchus-Associated Lymphoid Tissue (BALT) of the lungs.

One course of GcMAF-Forte is usually expected to be 10 doses for 10 weeks. Additional courses may be required depending on stage and type of disease, and based on disease symptoms, pathology and progress of improvement. Treatment with GcMAF-Forte should be continued as long as necessary while disease is present. Long term maintenance doses of GcMAF-Forte may be required depending on the type of disease. Maintenance doses are usually once a week administration.

As a general note, macrophage activation is always necessary for the effective functioning of the immune system to stay well and disease-free. GcMAF-Forte therapy should continue while there is disease present and for a period after to reduce the chance of recurrence for prevention.

Cancer: We recommend checking tumor markers and regular MRI, PET and CT scans.

Monocyte Count: A patients monocyte count will generally rise in the early stages of GcMAF treatment and indicates a response to GcMAF.

Increase in Monocyte percentage with High Dose GcMAF therapy

Monocyte percentage with High Dose GcMAF therapy

Increase in Monocyte number with High Dose GcMAF therapy

Monocyte number with High Dose GcMAF therapy

Example of monocyte count of Stage 4 Breast Cancer patient taking 2 ml GcMAF-Forte weekly by intramuscular injection during cancer treatment.

GcMAF-Forte has been clinically demonstrated to be free of any side effects in the great majority of patients. Only low-grade fever or eczema has been observed in only about 1 out of 10.000 patients using GcMAF-Forte, but these were short-term effects that are significantly less than occur with most other immunotherapies. In small numbers of patients local injection site skin reactions occur which can be easily treated with a local non-steroidal anti-inflammatory patch.

GcMAF-Forte can be safely used with a wide variety of other standard treatments and drugs to improve their effect. We refer to this as multimodality integrative medicine. Some therapies for cancer such as chemotherapy will reduce immune activity which will have some impact on GcMAF, however chemotherapy effectiveness can be increased in combination with GcMAF-Forte. Radiation for cancer has less negative impact on the immune system and the cancer killing effects helps macrophages to target the tumors and destroy it.

In combination with anti-cancer drugs and radiation therapy (radiotherapy) is possible. For maximum effect and benefit from GcMAF-Forte, administer a few days apart from chemotherapy. Radiation therapy does not have significant effects on Gc-MAF, so both can be used together at any time. In our clinical experience we have observed significant cancer killing effects from GcMAF-Forte combined with palliative radiotherapy in patients who have had significant prior treatment with chemotherapy.

GcMAF-Forte is usually combination with about 5,000 – 20.000IU vitamin D3 daily. Blood levels of vitamin D are often low in many kinds of diseases, such as cancer, HIV AIDS, etc. Normal vitamin D levels are necessary in order for GcMAF-Forte to work fully. Ask to have your blood 25 hydroxy-vitamin D as well as calcium levels tested. If blood calcium levels become elevated, the dose of vitamin D3 may need to be reduced to achieve optimal balance.

GcMAF-Forte can be safely used with a wide variety of drugs and other treatments however minimal use of steroids is desirable because of their immune suppressing effect, however they may be safely used with GcMAF-Forte if necessary and prescribed by your doctor.

Nagalase testing is not required for GcMAF-Forte therapy because macrophage activation is always necessary for the effective functioning of the immune system to destroy cancer cells, bacteria and viruses. GcMAF-Forte therapy should continue while there is disease present, regardless of Nagalase status. We advise cancer patients to do a Nagalase test, please ask us for more information.